MLTX MoonLake Immunotherapeutics

  1. Stocks
  2. Healthcare
  3. NASDAQ: MLTX

Price (delayed)

$18.79

Market cap

$1.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.87

Enterprise value

$1.19B

?
Relative Growth: Rel. Growth: 1
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 1

moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.

Highlights
The net income has dropped by 76% year-on-year and by 13% since the previous quarter
MoonLake Immunotherapeutics's EPS has shrunk by 68% YoY and by 10% QoQ
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of MLTX

MLTX stock price

How has the MoonLake Immunotherapeutics stock price performed over time
Intraday
2.85%
1 week
0.59%
1 month
7%
1 year
-63.19%
YTD
42.56%
QTD
0.8%

Financial performance

How have MoonLake Immunotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$267.37M
Net income
-$259.47M
Gross margin
N/A
Net margin
N/A
The net income has dropped by 76% year-on-year and by 13% since the previous quarter
The operating income has dropped by 57% year-on-year and by 9% since the previous quarter

Price vs fundamentals

How does MLTX's price correlate with its fundamentals

Growth

What is MoonLake Immunotherapeutics's growth rate over time

Valuation

What is MoonLake Immunotherapeutics stock price valuation
P/E
N/A
P/B
5.31
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
MoonLake Immunotherapeutics's EPS has shrunk by 68% YoY and by 10% QoQ
The price to book (P/B) is 42% lower than the 5-year quarterly average of 8.9 but 12% higher than the last 4 quarters average of 4.6
MLTX's equity is down by 38% YoY and by 17% QoQ

Efficiency

How efficient is MoonLake Immunotherapeutics business performance
The company's return on equity has shrunk by 173% YoY and by 27% QoQ
The ROIC has plunged by 163% YoY and by 38% from the previous quarter
The company's return on assets has shrunk by 112% YoY and by 20% QoQ

Dividends

What is MLTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MLTX.

Financial health

How did MoonLake Immunotherapeutics financials performed over time
MoonLake Immunotherapeutics's total assets is 174% more than its total liabilities
MLTX's quick ratio has dropped by 61% year-on-year and by 10% since the previous quarter
The current ratio has dropped by 59% year-on-year and by 7% since the previous quarter
The debt is 60% smaller than the equity
MoonLake Immunotherapeutics's debt to equity has surged by 111% YoY and by 60% QoQ
MLTX's equity is down by 38% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.